Eased symptoms, healed colons in 1 in 4 patients
Study found older adults with wide variations were more likely to show deterioration in thinking abilities
Despite difficulties, study finds most live independently
Younger and younger children are walking around with cell phones. Is your child ready for one? WebMD helps you figure it out.
Experimental wearable patch monitors biochemical, electrical signals to gauge heart, other functions
GlaxoSmithKline's new inhaled medicine Breo proved significantly better than standard care in a large British study that tested it in everyday use, providing a fillip for the product after the failure of another big trial in 2015. GSK said on Tuesday that the study, which tested Breo in day-to-day practice across the town of Salford, showed it was superior in reducing attacks of serious breathing difficulties in patients with chronic obstructive pulmonary disease (COPD). The success comes after another more traditional clinical trial in September found Breo failed to prolong life in COPD patients.
The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals. U.S. pharmaceuticals group Argentum Pharmaceuticals, which challenged UCB's patent, said in a statement late on Monday that the PTO had granted approval for a review of the sole remaining U.S. patent of UCB's Vimpat drug, due to expire in March 2022. The PTO had concluded that Argentum had established a "reasonable likelihood that it would prevail" in showing that certain claims made by UCB in the patent are "unpatentable", Argentum said, adding a decision was likely within a year.